Aeglea raises $50M in IPO after slashing share price

John Carroll Austin, TC-based Aeglea BioTherapeutics raised $ 50 million in its IPO after pricing 5 million shares at $ 10 each, far below the range that it had set out for itself. FierceBiotech ...

A-listers provide a $50M B round to AstraZeneca’s antibiotics spinout Entasis

John Carroll Last summer, AstraZeneca formally spun out its pared-down early-stage antibiotics unit in Waltham, MA, as Entasis Therapeutics, bequeathing a $ 40 million A round for ...

Mapi Pharma swings for $50M haul as oft-delayed IPO nears D-Day

Nick Paul Taylor Mapi Pharma has set the terms for its latest crack at listing on Nasdaq. The biotech, which set terms on its first IPO attempt back in April 2014, is aiming to round ...

Galapagos advances AbbVie-partnered CF drug; UCL forms £50M fund; Vasopharm bags €20M

Nick Paul Taylor In this week's EuroBiotech Report, the first of two correctors destined for use in Galapagos' triple-hit cystic fibrosis therapy is now in the clinic. With ...

UCL sets up £50M VC fund to support academic spinouts

Nick Paul Taylor University College London (UCL) is getting into the venture capital game. The university, which has spawned a host of biotechs, has rounded up £50 million ($ ...

Oxford BioMedica takes out $50M loan to service Novartis CAR-T alliance

Nick Paul Taylor Oxford BioMedica has secured a $ 50 million (€45 million) loan, half of which it will take out immediately to expand its laboratory and manufacturing facilities. ...

Cebix hangs it up after raising $50M for diabetes drug

Damian Garde La Jolla, CA's Cebix has quietly closed up shop, Xconomy reports, after its once-promising diabetes candidate failed to hit the mark in Phase IIb. FierceBiotech News

Blueprint Medicines banks $50M for its personalized take on cancer

Damian Garde Third Rock Ventures startup Blueprint Medicines has hauled in a $ 50 million C round, cash that'll see its way through clinical trials and keep its promising platform ...

Woodford buys $50M Prothena stake, Shire lacks ‘British gem’ status, French biotechs raise €100M

Nick Paul Taylor Welcome to the latest edition of our weekly EuroBiotech Report. We lead this week on news that Neil Woodford's much-discussed fund is starting to take shape, with ...

GlaxoSmithKline wires up $50M VC fund for bioelectronic treatment effort

John Carroll The pharma giant intends to back 5 to 7 drug and device startups in the bioelectronics field over the next 5 years in the latest example of GSK's commitment to come ...

NGM completes $50M Series C to advance cardio-metabolic therapies

Emily Mullin NGM Biopharmaceuticals has rounded up a $ 50 million Series C financing to advance the development of its portfolio of therapeutics to treat diabetes, obesity and other ...

Lilly backs $50M launch of public/private biotech research institute

John Carroll Eli Lilly and Roche Diagnostics have joined an industry consortium that will help launch a new research institute in Indiana that plans to hire a staff of about 100 investigators ...
Page 1 of 212
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS